CERO.US CERo Therapeutics Holdings, Inc. Common Stock

Healthcare Biotechnology USA Stocks
0.0050 USD
Close of Nov 14, 2026
0.0030 0.1350
Market cap
USD 358K
P/E
0.0x
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CERO.US undervalued?

Graham number

The Graham number of CERo Therapeutics Holdings, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CERo Therapeutics Holdings, Inc. Common Stock fundamental analysis

No fundamental analysis for CERo Therapeutics Holdings, Inc. Common Stock yet.

CERo Therapeutics Holdings, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CERo Therapeutics Holdings, Inc. Common Stock

CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.

Full company profile